2022

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

2021

Enanta Pharmaceuticals Announces Positive Data from Phase 1 Study of EDP-514 in Nucleos(t)ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection

Enanta Pharmaceuticals Announces Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic Chronic HBV Patients

Enanta Pharmaceuticals Adds COVID-19 to its Pipeline with the Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

2020

Enanta Pharmaceuticals’ HCV Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis

Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19

2019

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in a Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus

Enanta Adds Hepatitis B Virus to its Pipeline with the Initiation of Phase 1 Clinical Study of Core Inhibitor EDP-514

2018

Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

2017

Enanta Pharmaceuticals Announces that AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Received Approval in U.S., E.U. and Japan for the 8-Week Treatment Most Major Genotypes of Chronic Hepatitis C Infection

2016

Enanta Pharmaceuticals Announces Positive Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)

2015

Enanta Pharmaceuticals and AbbVie Announce European Commission Grants Marketing Authorization for AbbVie’s VIEKIRAX™

2014

Enanta Pharmaceuticals and AbbVie Announce FDA Approves VIEKIRA PAK®, AbbVie’s Combination Drug for the Treatment of Chronic Genotype 1 Hepatitis C Virus

2013

Enanta Pharmaceuticals Launches Initial Public Offering